Considering the close association between IGF1 levels and cognitive functions in clinical settings, our study reveals a new regulatory mechanism for IGF1 expression and function in AD pathology, thus providing a novel strategy for AD treatment. The gene discussed is IGF1; the disease is Alzheimer disease.